Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
BMJ Case Rep ; 15(9)2022 Sep 14.
Article in English | MEDLINE | ID: mdl-36104036

ABSTRACT

We report the case of a woman in her 60s with intravascular leiomyomatosis. She suffered from numerous non-specific symptoms including weight loss, anaemia and sudden swelling of the left lower extremity. CT imaging showed the presence of an enlarged left ovary and a thrombus extending from the left ovarian venous plexus intruding into the right atrium of the heart. Cancer antigen 125 was 20 U/mL. Pelvic transvaginal ultrasound examination identified two normal ovaries and a mass adjacent to the left ovary. A second opinion on the CT scan was requested at a oncogynaecological multidisciplinary team meeting, where the radiologist of the team identified an intervascular leiomyomatosis. After further investigation, surgical treatment was planned and completed in collaboration with the departments of cardiothoracic and vascular surgery. The patient recovered fully.


Subject(s)
Heart Neoplasms , Leiomyomatosis , Ovarian Diseases , Female , Heart Atria/diagnostic imaging , Heart Neoplasms/surgery , Humans , Leiomyomatosis/diagnostic imaging , Leiomyomatosis/surgery , Vena Cava, Inferior/surgery
2.
Ugeskr Laeger ; 180(20)2018 05 14.
Article in Danish | MEDLINE | ID: mdl-29761782

ABSTRACT

Vulvar intraepithelial neoplasia (VIN) is a rare but premalig-nant condition. VIN has two aetiological pathways: a human papillomavirus (HPV)-dependent pathway, which is a vulvar high-grade squamous intraepithelial lesion (HSIL), and an HPV-independent pathway, called differentiated VIN (d-VIN), associated with lichen sclerosus. d-VIN is more aggressive than vulvar HSIL. In case of symptoms, a biopsy should be performed. The recurrence risk is high: 25-50% regardless of treatment type. We recommend treatment with imiquimod as first choice to avoid mutilating surgery. Particular attention must be payed to immunosuppressed patients with VIN. HPV-vaccine can be discussed with patients with vulvar HSIL.


Subject(s)
Carcinoma in Situ , Vulvar Neoplasms , Antineoplastic Agents/therapeutic use , Carcinoma in Situ/classification , Carcinoma in Situ/drug therapy , Carcinoma in Situ/pathology , Carcinoma in Situ/virology , Female , Humans , Imiquimod/therapeutic use , Immunocompromised Host , Papillomaviridae/isolation & purification , Papillomavirus Infections/complications , Papillomavirus Vaccines/therapeutic use , Precancerous Conditions , Vulvar Neoplasms/classification , Vulvar Neoplasms/drug therapy , Vulvar Neoplasms/pathology , Vulvar Neoplasms/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...